Another point to consider is that all of the SGLT2 inhibitors that have successfully completed a number of phase III and phase IV RCTs (randomized controlled trials) share the reduced need for HF hospitalization as well as the renal protective effects. Here, SLC5A2 is linked to hydrops fetalis.